Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III (RE-GEND)
A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)
Sponsor: Japan Clinical Oncology Group
Listed as NCT02761070, this PHASE3 trial focuses on Glioblastoma and Progression and remains ongoing. Sponsored by Japan Clinical Oncology Group, it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 8 earlier versions
-
Oct 2021 — Apr 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Mar 2019 — Oct 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Clinical Oncology Group
- Kyorin University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bunkyō-Ku, Japan , Chiba, Japan , Chuo-shi, Japan , Fukuoka, Japan , Hidaka, Japan , Hirakata, Japan , Hirosaki, Japan , Hiroshima, Japan , Kagoshima, Japan , Kanagawa, Japan and 21 more locations